Aktuellt
SENASTE
Redeye comments on Isofol’s Q3 2022 report, and we expect the company to communicate a clearer path ahead in late Q1 2023e. Following its failed phase III AGENT trial, we believe that arfolitixorin holds little remaining value and has no commercially viable path to market. Therefore, we conclude that the company will liquidate itself or, e.g., enter a structural transaction in H1 2023e.
LÄS MER
